Onapristone: Additional Phase I data

Additional data from 52 evaluable postmenopausal women with progesterone receptor-positive tumors in the Phase I portion of an open-label, dose-escalation, French Phase I/II trial showed that oral onapristone led to a median PFS of 57.5 days and a CBR of 15%, including 1 partial response and 7 cases of stable disease lasting >=24 weeks. Onapristone was well tolerated. The most common grade >=3 treatment-related adverse events reported were asthenia, nausea, and elevated aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) and alanine aminotransferase (ALT) levels. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...